Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · September 11, 2023

Association Between Baseline LDH Levels and Immune-Related Adverse Events in Patients With Melanoma Receiving First-Line Immune Checkpoint Inhibitors

Journal of the American Academy of Dermatology


Additional Info

Journal of the American Academy of Dermatology
Association between baseline lactate dehydrogenase and immune-related adverse events among patients with melanoma varies by tumor stage at immune checkpoint inhibitor initiation
J Am Acad Dermatol 2023 Aug 07;[EPub Ahead of Print], CX Pan, WC Lau, DY Kim, CB Lau, R Rowley, R Kanwar, NR LeBoeuf, VE Nambudiri

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading